Fuxiang Pharmaceutical: Legal Opinion of Beijing Zhonglun Law Firm on the 2024 First Extraordinary General Meeting of Shareholders of Jiangxi Fuxiang Pharmaceutical Co., Ltd.
Fuxiang Pharmaceutical: Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders
Fuxiang Pharmaceutical: Announcement on Wholly Owned Subsidiaries Passing Drug GMP Compliance Tests
Fuxiang Pharmaceutical: Announcement on terminating the implementation of the second phase of the employee stock ownership plan
Fuxiang Pharmaceutical: Announcement on changing the company\'s business scope and revising the “Articles of Association”
Fuxiang Pharmaceutical: Notice on Convening the First Extraordinary General Meeting of Shareholders in 2024
Fuxiang Pharmaceutical: Announcement on changing the holding subsidiary to a wholly-owned subsidiary and completing the registration of commercial and commercial changes
Fuxiang Pharmaceutical: Announcement on the company being recognized as the sixth batch of national specialized, special, and new small giant enterprises
Fuxiang Pharmaceutical: Notice on the Subsidiary Obtaining a Renewed “Pharmaceutical Production License”
Fuxiang Pharmaceutical: Special Report on the Occupation of Non-operating Funds and Other Related Capital Transactions for the Semiannual Year of 2024
Fuxiang Pharmaceutical: Prompt Announcement on the Disclosure of the 2024 Semi-Annual Report
Jiangxi Fushine Pharmaceutical: Announcement regarding completion of industrial and commercial registration changes and issuance of new business license for subsidiary under control.
Jiangxi Fushine Pharmaceutical: Announcement regarding the acquisition of an invention patent certificate by a wholly-owned subsidiary.
Jiangxi Fushine Pharmaceutical: Announcement regarding the overseas listing of the company's invested companies.
Jiangxi Fushine Pharmaceutical: Announcement on the signing of the “Agreement on Termination of Special Shareholders' Rights”
Jiangxi Fushine Pharmaceutical: Notice on the holding subsidiary completing the registration of industrial and commercial changes and issuing a business license
Jiangxi Fushine Pharmaceutical: Announcement on the progress of the company's provision of guarantees to wholly-owned subsidiaries
Jiangxi Fushine Pharmaceutical: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Jiangxi Fushine Pharmaceutical: Legal Opinion of Beijing Zhonglun Law Firm on the 2023 Annual General Meeting of Shareholders of Jiangxi Fuxiang Pharmaceutical Co., Ltd.
Jiangxi Fushine Pharmaceutical: Announcement on Wholly-owned Subsidiaries Passing Pharmaceutical GMP Compliance Checks
No Data
No Data